Loading Complete
Janis M. Taube

Janis M. Taube, MD

Dermatopathology

Pathology

Johns Hopkins Affiliations:
  • Johns Hopkins School of Medicine Faculty

Languages

  • English

14 Insurances Accepted

View all

Gender

Female

About Janis M. Taube

Professional Titles

  • Director, Division of Dermatopathology
  • Co-Director Tumor Microenvironment Laboratory, Bloomberg ~Kimmel Institute for Cancer Immunotherapy
  • Co-Director Mark Foundation Center for Advanced Genomics and Imaging

Primary Academic Title

Professor of Dermatology

Background

Dr. Janis Taube is a professor of dermatology and pathology at the Johns Hopkins University School of Medicine and a member of the Johns Hopkins Kimmel Cancer Center. Her area of clinical expertise is dermatopathology. Dr. Taube serves as the Director of the Division of Dermatopathology and as the Assistant Director of the Dermatoimmunology Laboratory at the School of Medicine.

Dr. Taube received her undergraduate degree in engineering from Duke University. She earned her M.D. from Tulane University and her M.Sc. in molecular medicine from University College London. She completed her residency in pathology at Johns Hopkins where she also served as the chief resident, before undertaking a dermatopathology fellowship at Stanford University. In 2009, Dr. Taube returned to Johns Hopkins for her certification in the Melanoma Clinic.

She is one of the lead scientific researchers in the Department of Dermatology at Johns Hopkins. She has written over 180 peer-reviewed publications, and her research has been cited over 70,000 times.

In addition to running her own research laboratory, she serves as the co-Director of the Mark Foundation Center for Advanced Genomics and Imaging and also as the co-Director of the Tumor Microenvironment Core Laboratory for the Bloomberg~Kimmel Institute for Cancer Immunotherapy.

Additional Academic Titles

Professor of Pathology, Professor of Oncology

Research Interests

and other cutaneous neoplasms, Merkel cell carcinoma, Prognostic and predictive value of the immunoarchitecture of melanoma

Research Summary

Dr. Taube’s research interests center on the immune evasion by solid tumors, specifically studying the PD-L1/PD-1 axis, and the identification of potential biomarkers that can help pre-select patients with advanced malignancies for novel immunotherapeutic treatment regimens. This requires a focus on immunohistochemical and molecular methods for identifying cell surface antigens and signaling pathways in paraffin-embedded tissue. Dr. Taube’s lab described PD-L1 (B7-H1)-mediated adaptive immune resistance by melanoma, a finding which has now been extended to other tumor types. Dr. Taube’s laboratory also developed the PD-L1 immunohistochemical assay and scoring system for the first in-human anti-PD-1 and anti-PD-L1 immunotherapies, versions of which are now FDA approved. Ongoing laboratory efforts focus on further characterizing the local, pre-treatment tumor microenvironment with the aim of developing rational treatment combinations and improving patient selection algorithms for immunotherapeutic regimens. To that end, Dr. Taube has been collaborating with Dr. Szalay, a world expert in Astronomy and Big Data, to develop a new multispectral tissue imaging platform termed ‘AstroPath’ to further biomarker development. 

Selected Publications

  • Taube JM, Anders RA, Young GD, Xu H, Sharma R, Klien A, Topalian SL, Chen L. Colocalization of inflammatory response with B7-H1 [PD-L1] expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra37

  • Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064-74

  • Berry S, Giraldo NA, Green BF, Cottrell TR, Stein JE, Engle EL, Xu H, Ogurtsova A, Roberts C, Wang D, Nguyen P, Zhu Q, Soto-Diaz S, Loyola J, Sander IB, Wong PF, Jessel S, Doyle J, Signer D, Wilton R, Roskes JS, Eminizer M, Park S, Sunshine JC, Jaffee EM, Baras A, De Marzo AM, Topalian SL, Kluger H, Cope L, Lipson EJ, Danilova L, Anders RA, Rimm DL, Pardoll DM, Szalay AS, Taube JM. Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. Science. 2021;372(6547):eaba2609

  • Lu S, Stein JE, Rimm DL, Wang DW, Bell JW, Johnson DB, Sosman JA, Schalper KA, Anders RA, Wang H, Hoyt C, Pardoll DM, Danilova L, Taube JM. Comparison of Biomarker Modalities for Predicting Response to PD-(L)1 Checkpoint Blockade: A Systematic Review and Meta-Analysis. JAMA Oncol. 2019 Jul 18.[Epub ahead of print]

Memberships

  • American Society of Dermatopathology
  • College of American Pathologists
  • Dermatology Foundation
  • United States and Canadian Academy of Pathology

Locations

  1. The Johns Hopkins Hospital
    • 1800 Orleans Street, Baltimore, MD 21287

    Expertise

    Education

    Stanford University School of Medicine

    Fellowship, Dermatopathology, 2009

    Johns Hopkins University School of Medicine

    Residency, Pathology, 2008

    Tulane University School of Medicine

    Medical Education, MD, 2004

    Board Certifications

    Dermatopathology

    American Board of Pathology, 2009

    Anatomic Pathology

    American Board of Pathology, 2008

    Insurance

    Johns Hopkins providers accept various commercial health insurance plans. However, they may not be included in all of an insurance company's plans or offerings. This may include Exchange, Medicaid, Medicare, and specific limited benefit plans. Exceptions to participation also exist based on your employer’s benefits package and the provider's location or specialty. Please contact your insurer directly to make sure your doctor is covered by your plan. For more details, please review our Insurance Information.
    Search plans
    • Aetna
    • CareFirst
    • Cigna
    • First Health
    • Geisinger Health Plan
    • HealthSmart/Accel
    • Humana
    • Johns Hopkins Health Plans
    • MultiPlan
    • Pennsylvania's Preferred Health Networks (PPHN)
    • Point Comfort Underwriters
    • Private Healthcare Systems (PHCS)
    • UnitedHealthcare
    • Veteran Affairs Community Care Network (Optum-VACCN)